New insights on the addictions of tumors

October 6, 2017
Dr. Diaz-Meco is a professor in SBP's NCI-designated cancer. Credit: James Short

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego have shown that tumors can ensure a more reliable nutrient supply by eliminating the p62 protein in surrounding stromal tissue. Specifically, p62 deficiency helps tumors and stroma (supportive tissue outside the tumor) survive and grow, despite being deprived of glutamine, an essential amino acid.

The study, published October 5 in Cell Metabolism, suggests that the p62 pathway in could be a potential anti-cancer target. "Cancer has traditionally been treated with chemotherapies that target oncogene addictions—the oncogenic signals that tumors use to survive," says Maria Diaz-Meco, Ph.D., professor at SBP's NCI-designated Cancer Center and senior author of the paper. "We are looking at the non-oncogenic addictions, which are the function of non-mutated genes that also contribute to the survival of many cancers."

"For example, the stroma is not the cancer, but it's a major component that supports the tumor," explains Diaz-Meco. "We believe that targeting metabolism, not only in mutated but also in the stroma, will be a way to find new therapies, regardless of the cancer's mutations."

Tumors must develop unique mechanisms to ensure adequate nutrient supplies. To do this, they rewire surrounding tissue, particularly cancer-associated fibroblasts in the stroma, which are hijacked to do the tumor's bidding. Essentially, the cancer remodels its nest.

"What happens when there's nutrient stress?" asks Diaz-Meco. "The cancer doesn't have supplies. In its more aggressive forms, nutrient accessibility inside the tumor becomes limited. The tumor eliminates p62 from the stroma to make the stroma more aggressive, more inflammatory and to be able to support the disease."

This is a common strategy in cancer, as p62 is often missing from stroma in breast, prostate, liver and other tumors.

Diaz-Meco, along with fellow authors Jorge Moscat, Ph.D., professor and deputy director of SBP's NCI-designation Cancer Center, and Christian Metallo, Ph.D., associate professor of bioengineering at UC San Diego, believe this stromal support could offer compelling ways to interfere with tumor supply lines. Because tumors are addicted to these mechanisms, it may be possible to target them without encountering significant resistance.

"This offers new strategies to take advantage of the tumor's vulnerabilities," says Diaz-Meco. "We hope that targeting non-oncogenic addictions will generate less resistance, because the stroma is more genetically stable and does not mutate as tumor do during aggressive therapies."

In the study, the team found that reducing p62 increased ATF4, an essential transcription factor protein that instructs cells to adapt to situations in which nutrients are at a premium in the . ATF4 levels only changed in stroma, remaining constant in epithelial cells, regardless of p62 levels.

Without ATF4, stromal cells in glutamine-free media stopped growing. Further exploration showed that p62 played a critical role in breaking down ATF4, accounting for the high levels in low-glutamine conditions.

Ultimately, losing p62, and gaining ATF4, activates a complex pathway that generates the amino acid asparagine, which allows , and ultimately tumor cells, to survive and grow despite the nutrient-poor conditions. From a therapeutic angle, this forces the tumor to become reliant on this pathway, making ATF4 a potential vulnerability to be exploited to undermine cancer growth.

Up to this point, p62 has been viewed exclusively as a promoter due to its role in the tumor epithelial cells. That it plays such a different role in stroma, underscores how complex these molecular relationships can be. The authors believe it's time to take a harder look at stroma and how it supports .

"The role of the stroma is understudied," says Diaz-Meco, "There have been very few papers on how stromal metabolism affects . We really need to understand more about this basic rewiring to develop more efficacious and less toxic therapeutic opportunities."

Explore further: New study reveals how tumors remodel their surroundings to grow

More information: Cell Metabolism (2017). DOI: 10.1016/j.cmet.2017.09.001

Related Stories

New study reveals how tumors remodel their surroundings to grow

July 3, 2014
A team of scientists from Sanford Burnham Medical Research Institute (Sanford-Burnham) has found that the loss of a protein called p62 in the cells and tissue surrounding a tumor can enhance the growth and progression of ...

Ovarian cancer cells hijack surrounding tissues to enhance tumor growth

September 4, 2012
Tumor growth is dependent on interactions between cancer cells and adjacent normal tissue, or stroma. Stromal cells can stimulate the growth of tumor cells; however it is unclear if tumor cells can influence the stroma.

How cancer cells rewire their metabolism to survive

January 31, 2013
Cancer cells need food to survive and grow. They're very good at getting it, too, even when nutrients are scarce. Many scientists have tried killing cancer cells by taking away their favorite food, a sugar called glucose. ...

Tumor-infiltrating B lymphocytes promote melanoma progression and resistance to therapy

September 19, 2017
In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells ("TABs") in melanoma ...

New study on popular prostate cancer protein provides insight into disease progression

June 25, 2013
Researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute have uncovered for the first time the vital role a popular protein plays in the stroma, the cell-lined area outside of a prostate tumor.

Pancreatic tumors rely on signals from surrounding cells

January 19, 2017
Just as an invasive weed might need nutrient-rich soil and water to grow, many cancers rely on the right surroundings in the body to thrive. A tumor's microenvironment—the nearby tissues, immune cells, blood vessels and ...

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.